ArticleeLife2016
A bacteriophage endolysin that eliminates intracellular streptococci.
Article in eLife, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 76 citations in OpenAlex.
- A teichoic acid-like wall modification associated with immune suppression is socially regulated inmBio · 2026Article
- Physicochemical and Proteolytic Barriers Limiting Activity of Cpl-1 and Pal Endolysins in Human Circulation.Current issues in molecular biology · 2026Article
- Clinical implementation of endolysins targeting gram-positive bacteria points toward a combination strategy with standard-of-care antibiotics: a selective review.European journal of medical research · 2026Review
- A teichoic acid-like wall modification associated with immune suppression is socially regulated inbioRxiv : the preprint server for biology · 2026Article
- Article
- New Perspectives in the Fight Against Multidrug-Resistant Bacteria: The Potential of Endolysin Biocomposites.Antibiotics (Basel, Switzerland) · 2025Review
- Structure and mechanism of biosynthesis of Streptococcus mutans cell wall polysaccharide.Nature communications · 2025Article
- LysJEP8: A promising novel endolysin for combating multidrug-resistant Gram-negative bacteria.Microbial biotechnology · 2024Article
- Bacteriophage-derived endolysins as innovative antimicrobials against bovine mastitis-causing streptococci and staphylococci: a state-of-the-art review.Acta veterinaria Scandinavica · 2024Review
- Development of engineered endolysins with in vitro intracellular activity against streptococcal bovine mastitis-causing pathogens.Microbial biotechnology · 2023Article
- Expression of a recombinant endolysin from bacteriophage CAP 10-3 with lytic activity against Cutibacterium acnes.Scientific reports · 2023Article
- Thermal Characterization and Interaction of the Subunits from the Multimeric Bacteriophage Endolysin PlyC.Biology · 2023Article
- Identification of Toxic Proteins Encoded by Mycobacteriophage TM4 Using a Next-Generation Sequencing-Based Method.Microbiology spectrum · 2023Article
- Immunogenicity of Endolysin PlyC.Antibiotics (Basel, Switzerland) · 2022Article
- Targeted Antimicrobial Photodynamic Therapy of Biofilm-Embedded and Intracellular Staphylococci with a Phage Endolysin's Cell Binding Domain.Microbiology spectrum · 2022Article
- Novel Phage Lysin Abp013 againstAntibiotics (Basel, Switzerland) · 2022Article
- Endolysins against Streptococci as an antibiotic alternative.Frontiers in microbiology · 2022Review
- Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.Antibiotics (Basel, Switzerland) · 2021Review
- Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections.Antibiotics (Basel, Switzerland) · 2021Review
- Molecular basis for recognition of the Group A Carbohydrate backbone by the PlyC streptococcal bacteriophage endolysin.The Biochemical journal · 2021Article
Corrections and comments
- Commented on byA lysin to kill.2016
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
Abstract
PlyC, a bacteriophage-encoded endolysin, lyses Streptococcus pyogenes (Spy) on contact. Here, we demonstrate that PlyC is a potent agent for controlling intracellular Spy that often underlies refractory infections. We show that the PlyC holoenzyme, mediated by its PlyCB subunit, crosses epithelial cell membranes and clears intracellular Spy in a dose-dependent manner. Quantitative studies using model membranes establish that PlyCB interacts strongly with phosphatidylserine (PS), whereas its interaction with other lipids is weak, suggesting specificity for PS as its cellular receptor. Neutron reflection further substantiates that PlyC penetrates bilayers above a PS threshold concentration. Crystallography and docking studies identify key residues that mediate PlyCB-PS interactions, which are validated by site-directed mutagenesis. This is the first report that a native endolysin can traverse epithelial membranes, thus substantiating the potential of PlyC as an antimicrobial for Spy in the extracellular and intracellular milieu and as a scaffold for engineering other functionalities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.